Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01660763 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery
A Phase 3 study, sponsored by Talphera.
- Completed
- Registry status
- Phase 3
- Development phase
- 419
- Enrollment target
NCT01660763: Completed Phase 3 study, sponsored by Talphera.
NCT01660763 is a Phase 3 study that has completed, run by Talphera. The registered enrollment target is 419 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01660763, a Phase 3 study, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 419 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of the Sufentanil NanoTab PCA System/15 mcg to the Placebo Sufentanil NanoTab PCA System for the management of acute moderate to severe post-operative pain after total unilateral knee or total unilateral hip replacement surgery.
Primary Outcome
SPID-48 is the sum of the pain intensity difference (PID) over the 48 hour time period. A pain intensity score of 0 (no pain) to 10 (worse possible pain) is obtained before starting the study and throughout the 48 time period. The pain score at each assessment time is subtracted from the baseline pain score to provide the total sum score or SPID-48. A higher SPID-48 is better and indicates a reduction in pain intensity compared to the baseline score. Range of SPID48 scores were -239 to 417. Tim
Interventions
- DRUG Sufentanil NanoTab PCA System/15 mcg
- DRUG Placebo Sufentanil NanoTab PCA System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT01660763 record still lists
NCT01660763 is an interventional study that assigns participants to a tested intervention. The registered 419 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 2 interventions - of which Sufentanil NanoTab PCA System/15 mcg is the first listed.
NCT01660763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01660763 about?
NCT01660763 is a clinical study titled "Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery". The purpose of this study is to compare the efficacy and safety of the Sufentanil NanoTab PCA System/15 mcg to the Placebo Sufentanil NanoTab PCA System for the management of acute moderate to severe post-operative pain after total unilateral knee or total unilateral hip replacement surgery.
What is the current status of trial NCT01660763?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2012-08. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01660763?
The interventions under investigation include: Sufentanil NanoTab PCA System/15 mcg (DRUG), Placebo Sufentanil NanoTab PCA System (DRUG).
Who is sponsoring clinical trial NCT01660763?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01660763's enrollment target sits among peer trials
419 899th of 2000 higher than 1,101 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia